Objectives: HMG CoA reductase inhibitors reduce cellular availability of mevalonate, a precursor in cholesterol synthesis. Since the 1 1 cholesterol content of cell membranes is an important determinant of Na -K pump function we speculated that treatment with HMG 1 1
Introduction
inhibitors, and in vitro exposure to the HMG-CoA reductase inhibitor lovastatin causes a large reduction in the Modification of the cholesterol content of cell memcholesterol content of some cells [5] . As HMG-CoA 1 1 branes in vitro alters Na -K pump function (see Refs. reductase inhibitors are widely used in clinical practice it is [2] and [26] for reviews). A possible physiological releimportant to establish if treatment with these drugs in vivo 1 1 vance of this is suggested by the finding that a modest can inhibit the Na -K pump. We have examined the diet-induced increase in serum cholesterol above control effect of treatment with lovastatin on the sarcolemmal 1 1 levels stimulates pump activity [9] . Since dietary cholesNa -K pump. 1 1 terol supplementation can enhance Na -K pump function it is reasonable to think that a decrease in cellular cholesterol induced by inhibition of endogenous choles-2. Methods terol synthesis may reduce pump activity.
Cholesterol synthesis can be inhibited by blocking the Male New Zealand White rabbits weighing 2.5-3.0 kg conversion of 3-hydroxy-3-methyl-glutaryl CoA (HMGand female Wistar rats weighing 125-150 g were used. We CoA) to mevalonate with specific HMG-CoA reductase gave rabbits a gelatin capsule containing 10 mg lovastatin plus 230 mg lactose orally each day for 2 weeks (dose adopted from Ref. [19] ). Control rabbits received capsules mM. The composition has been described in detail previcontaining 240 mg lactose for the same period. The dose of ously [9] . Filled pipettes had resistances of 0.8-1.1 MV. 21 lovastatin is |50-fold lower than the toxic dose for the Myocytes were initially superfused with modified Caspecies [15] . We gave rats 10 or 30 mg lovastatin via a containing Tyrode's solution. When the whole cell configugastric tube with 1 ml water daily (dose adopted from Ref. ration had been established the superfusate was changed to 21 [25] ). Control rats were given the same amount of water. one that was nominally Ca -free. In some experiments 1 Treatment with lovastatin was well tolerated and there was the K concentration was varied between 0 and 15 mM. 1 no effect on body weight in either species. The Na concentration in these solutions was maintained Some rabbits treated with lovastatin received parenteral at 140 mM. TMA.C1 was used to maintain a constant mevalonate via osmotic minipumps (ALZET microosmolality. The composition has been described in detail osmotic minipump Model 1003D) for the second week of previously [9] . I was defined as the shift in holding p the dosage period. We implanted two 100 ml minipumps in current induced by 50 mM ouabain [11] unless indicated the interscapular region under a brief general anaesthetic of otherwise. Membrane currents were recorded using the 2% halothane with two parts nitrous oxide and one part continuous single electrode voltage clamp mode of an O . Implantation of pumps containing only distilled water Axoclamp-2A amplifier [9] , and is reported normalised for 2 1 1 had no effect on the Na -K pump (unpublished observamembrane capacitance [24] except where indicated. We 1 i tions). Each pump contained 200 mg mevalonate dissolved measured the intracellular Na activity (a ) using ionNa in water. The substance was administered at a rate of 1 sensitive microelectrodes. Details have been described 1 mg / h from each pump. In addition, to ensure adequate previously [10] . Tissue K content was measured by flame systemic levels, a dose of 120 mg mevalonate dissolved in photometry as described [4] . 1 ml normal saline was injected daily via a marginal ear K -dependent pNPPase activity was determined in vein. High cholesterol diets were prepared as published crude homogenates with a tissue concentration of 10 mg / 1 previously [9] . Blood was taken from a marginal ear vein ml. The K -dependent pNPPase activity was determined for estimation of serum cholesterol in some rabbits [9] .
as the difference measured in buffers containing (in mM): At the end of the treatment period rabbits were anaes-25 histidine, 15 MgCl and 100 NaCl (pH 7.4) or 25 2 thetised with intramuscular xylazine hydrochloride (20 histidine, 15 MgCl and 50 KC1 (pH 7.4). Details have 2 3 mg / kg) and ketamine hydrochloride (50 mg / kg). Once been described previously [16] . Vanadate-facilitated Hdeep anaesthesia was achieved the heart was excised and ouabain binding to 2-4 mg (wet weight) intact samples single ventricular myocytes were isolated [10] . Myocytes was performed as previously described [13] . Tissue water were used on the day of isolation only. Rats were content was determined as the relative reduction in weight decapitated and the heart and gastrocnemius muscle exafter heating samples at 908C until weight stabilisation, cised. Heart weight was determined immediately after and tissue protein was determined according to the method excision and samples of left ventricular myocardium and of Lowry et al. [18] . gastrocnemius muscle were taken for determination of Cholesterol, phospholipid and protein contents were 1 1 K -dependent pNPPase activity and water and K content. measured in rabbit hearts that had been frozen previously All procedures were in accordance with guidelines of and stored at 2208C. ty and H-ouabain binding site concentration were of analytical grade and purchased from Bie and Berntsen (Denmark). All other chemicals were analytical grade and purchased from BDH (Australia) Results are expressed as means6S.E. Statistical comparisons were made using Student's t-test for unpaired observations. Dunnett's test was used when the same control group was used for more than one comparison. Non-linear regression was used for fitting of the Hill equation to data. A P value of ,0.05 was regarded as statistically significant. pipettes containing 80 mM Na to nearly saturate intracel-
lular Na -K pump sites. The test potential was 240 mV.
1
Examples of traces of holding currents from a myocyte near-maximal Na -K pump activity is reduced by the isolated from a control rabbit and a rabbit treated with treatment. lovastatin are shown in Fig. 1 from the lovastatin-treated group was significantly lower with pipettes containing 10 mM Na . As expected, mean than mean I of myocytes from controls. We conclude that levels of I , shown in Fig. 2 , were much lower than mean p p levels measured using a [Na] of 80 mM. However, the pip relative decrease in I induced by lovastatin was similar for p the two groups of experiments.
Cholesterol, mevalonate and I p
To examine if changes in I induced by treatment with p lovastatin might be related to changes in cholesterol status we gave two rabbits a diet containing 1% cholesterol for 2 weeks. They were also given lovastatin. The serum cholesterol levels were 5.9 and 4.6 mmol / l (serum cholesterol of control rabbits is |1 mmol / l, see Ref. [9] ). Mean I of p myocytes isolated from these rabbits was similar to the mean I of the rabbits given lovastatin and no dietary p cholesterol supplementation (Fig. 2) . To examine the effect of a wide range in serum cholesterol levels on I we gave (data not shown). The mean I of myocytes from all six p rabbits is included in Fig. 2 Na is at a level expected to cause near-maximal pump stimulation.
We also examined if lovastatin altered cardiac cholesterol content. We analysed left ventricular tissue from five control rabbits and from five rabbits given lovastatin. The diets were not supplemented with cholesterol. The cholesterol:phospholipid ratios (mol / mol) were 0.3560.02 and 0.3860.04 respectively. The difference was not significant. Cholesterol contents normalised to total protein were 10.860.44 and 13.362.55 nmol / mg protein. The difference was not significant. Taken together, the absence of an effect of dietary cholesterol on the lovastatin-induced pump inhibition and the absence of an effect of lovastatin on cardiac cholesterol content strongly suggest the effect of lovastatin on I is independent of any effect of the drug 
3.3.
Lovastatin and Na -K pump current-voltage maximal pump activation was 2.8 for myocytes from relationship rabbits treated with lovastatin and 2.9 for myocytes from control rabbits. The Hill coefficients were 1.3 and 1.3. We next examined the effect of lovastatin on the voltage dependence of I . After establishing the whole cell conp figuration myocytes from rabbits treated with lovastatin and from controls were voltage clamped at a potential of 240 mV. We then applied voltage steps in 20 mV increments to test potentials (V ) from 2100 to 160 mV. m Details of the voltage clamp protocol and an example of representative membrane currents have been published previously [9] . The mean I -V relationships, normalised p m to the I measured at 0 mV [9] , for the myocytes from the p two groups of rabbits are shown in Fig. 3 . The slopes were similar. ranging from 0 to 15 mM. Patch pipettes contained 80 mM Experiments on 9 myocytes from 3 treated rabbits and 13 myocytes from 1 Na . Details of the experimental protocol used to study the 3 control rabbits are summarised. Pump currents have been normalised to 1 apparent K affinity have been published previously [9] . To examine if lovastatin can affect the sarcolemmal 8.961.0 mM in Na papillary muscles from 10 rabbits
Na -K pump in an animal that is more resistant to treated with lovastatin and 6.360.5 mM in papillary HMG-CoA reductase blockade than rabbits we performed muscles from 9 controls. The difference was statistically experiments on rats. Rats have been used extensively in significant. We also examined if treatment had an effect on
previous studies on HMG-CoA reductase inhibitors. They Na influx by measuring the rate of rise in a upon Na were treated with 10 or 30 mg lovastatin per day for 2 sudden pump blockade with the fast-acting cardiac steroid weeks. Controls had placebo treatment. We used 5-6 rats dihydroouabain as described previously [10] . There was no in each treatment group. Treatment had no effect on heart difference between the two groups. content. Because the rat cardiac Na -K pump has a low rats given either 10 mg or 30 mg lovastatin per day and affinity for cardiac glycosides we examined the effect of 7861 mmo1 / g wet wt. in 11 control rats. This difference concentration. Mean myocardial K -dependent pNPPase lovastatin and 10761 mmol / g wet wt. in 10 control rats. activities for control rats and rats treated with lovastatin This difference was not statistically significant. are shown in the Table 1 . Activities in both treated groups were significantly lower than the activity in the myocar-1 dium of control rats. Gastrocnemius K -dependent 4. Discussion pNPPase activity of rats treated with 10 mg lovastatin per day was not significantly different from controls (see Table  Treatment with lovastatin induced a decrease in I , p 3 1). However, there was a significant reduction relative to H-ouabain binding and K-dependent pNPPase activity. controls in the activity in muscles from rats treated with 30
The absence of an effect on heart weight, tissue water or mg per day.
protein content indicates that lovastatin did not induce a 3 H-ouabain binding concentration cannot be measured generalised reduction in protein synthesis. Treatment was 1 1 in rat heart. However it can be measured in rat skeletal associated with a reduction in the total amount of Na -K ATPase per heart, indicating that the decrease in Na -K glycosylation in cultured cells exposed to HMG CoA ATPase concentration was not due to an increase in reductase inhibitors in concentrations much higher than myocardial mass relative to membranes. The absence of an those expected under the in vivo conditions of the present 1 effect of treatment on the apparent K affinity and on the study [3, 5] . An effect on isoprenylation is thought to 2 voltage dependence of I suggests that treatment did not underlie lovastatin-induced inhibition of Cl secretion in p merely induce a functional change in existing pumps. cultured colonic cells [5] . However, the lovastatin levels Taken together, the results of the studies in rabbits and rats required to inhibit isoprenylation are high, likely to cause strongly support the conclusion that lovastatin caused a cytotoxicity [22] and not expected to be achieved with the 1 1 reduction in the density of functional Na -K pump units dosage schedule we used. An effective specific inhibitor of i and an increase in a . protein isoprenylation is not available [3] . The same Na applies to a large extent to the other steps in the mevalo-4.1. Potential mechanisms for effects of lovastatin on nate pathway. This has made it very difficult to firmly the pump establish which step in this complex pathway is important in cellular effects of HMG CoA reductase inhibition, even The effect of lovastatin was independent of effects on under in vitro conditions that allow selective control of 1 1 known determinants of Na -K pump activity. There was substrate concentrations. The same difficulty is encounno difference in body weight between treated and control tered with an ex vivo model such as that used in the animals in either rabbits or rats to suggest that semistarvapresent study, and it would be difficult to firmly establish tion or protein deprivation caused pump inhibition [14] .
the mechanism for the lovastatin-induced pump inhibition. We are unaware of studies indicating that lovastatin 1 increases renal K excretion, and we observed no other 
4.2.
Implications of lovastatin-induced Na -K pump cause for K depletion in either rabbits or rats. It is inhibition therefore unlikely that the effect of lovastatin was sec-1 ondary to changes in the K balance, a known regulator of 1 The clinical usefulness of treatment with HMG CoA the pump, and the decrease in myocardial K content with reductase inhibitors for coronary artery disease is well lovastatin treatment is therefore likely to be a consequence 1 1 established. However, inhibition of the Na -K pump rather than a cause of pump inhibition.
could have some adverse clinical consequences. When Lovastatin had no effect on I when the product of
combined with a decrease in sarcolemmal Na -K pump HMG CoA reductase, mevalonate, was administered the concentration in heart failure [1] and a decrease in pump week before rabbits were sacrificed. This indicates that function induced by therapeutic use of cardiac glycosides HMG CoA reductase inhibition rather than a direct effect This, in turn, would affect intracellular levels of several levels of a product of the mevalonate pathway. Such a 1 ions because of the existence of Na -dependent co-and product could have a direct effect on the pump or an effect counter-transporters in the sarcolemma. Adverse conseon one of its regulators.
quences might include cardiac arrhythmias, a common Since lovastatin can inhibit a cAMP-activated process complication of heart failure and digitalis toxicity. [5, 17] and since cAMP is reported to regulate the sar-
Na -K pump inhibition might also affect vascular colemmal Na -K pump [6] one might speculate that the tone. Exposure of both rat and human resistance vessels to lovastatin-induced pump inhibition in this study was lovastatin for 48 h in vitro causes an increase in the related to an effect on cAMP. However, cAMP-mediated 21 intracellular Ca concentration, enhances responsiveness effects are more likely to affect functional properties of the to vasoconstrictors and impairs responsiveness to vasodipump than influence pump density. Pump density was lators. These effects are reversed by coadministration of affected by treatment while there was no effect on funci mevalonate [21] . A lovastatin-induced increase in a may tional properties. Na 21 Cholesterol synthesis and glycosylation and isoprenylahave caused an increase in the intracellular Ca contion of proteins depend upon the mevalonate pathway. The centration and hence an increase in vascular tone. A role of these processes in the lovastatin-induced pump similar sequence of events in vivo might cause an increase inhibition should be considered. Cholesterol seems unlikein blood pressure. ly to be involved because there was no effect of treatment Effects of sarcolemmal Na -K pump inhibition are 21 on cardiac cholesterol content, and dietary cholesterol usually attributed to changes in intracellular Ca and the supplementation had no effect on the lovastatin-induced contractile state of myocytes. However, pump inhibition decrease in pump activity (Fig. 2) . Since the b-subunit of probably has a more pervasive impact. In cardiac myocytes 1 the Na -K pump is heavily glycosylated [7] impaired pump inhibition causes an increase in the production of glycosylation might reduce expression of pumps in the reactive oxygen species and activation of growth-related membrane. However, there is no evidence of a reduction in genes [27] . A similar effect of pump inhibition might [11] Hool LC, Gray DF, Robinson BG, Rasmussen HH. Angiotensin contribute to the myopathy that can occur during treatment 
